Jun 26, 2009
A provider of contract laboratory services and manufacturer of scientific instruments in the US, has opened a new European laboratory and office in Warwickshire, UK.
 |
Jun 26, 2009
The Biotechnology and Biological Sciences Research Council (BBSRC) is launching a consultation on Next Generation Sequencing Technologies. The council is seeking comments from individuals and organizations from the UK?s academic and industrial research community about the potential impacts that these technologies can have on research in biosciences.
 |
Jun 18, 2009
Faculty of Health Sciences at the University of Copenhagen will open the doors of its new research centre, The Novo Nordisk Foundation Centre for Protein Research. The centre is the result of an historic donation from the Novo Nordisk Foundation, which in 2007 gave the university 80 million for its establishment.
 |
Jun 5, 2009
PerkinElmer and LEAP Technologies have entered into a resale agreement for ultra high performance liquid chromatography (UHPLC) and high performance liquid chromatography (HPLC) technology.
 |
 | Apr 1, 2009 By:Ronald E. Majors
Ron Majors brings readers the second part of his yearly review of all that was new and innovative at the annual Pittsburgh Conference.
 |
Apr 1, 2009 By:R.D. McDowall
This column discusses the similarities and differences between the validation approaches for analytical methods for QC product analysis and bioanalysis.
 |
Apr 1, 2009
A rapid and simple high performance liquid chromatography (HPLC) method with basic extraction assays was developed to investigate free diazepam levels in the plasma and urine samples of patients medicated with this drug for the management of alcohol withdrawal syndrome. The HPLC analysis was optimized and evaluated for linearity, imprecision, recovery, detection and quantification limits. The method showed linearity between 50–500 ng/mL (r2 ≥ 0.990). Coefficients of variations (%CV) were calculated to be in the range of 1.77–9.60. According to ICH guidelines, theoretical limits of detection (LOD) and quantification (LOQ) for plasma and urine were calculated as 8.3 ng/mL, 27.5 ng/mL and 8.2 ng/mL, 26 ng/mL respectively. Diazepam monitoring in plasma and urine displayed remarkable variations. The importance of adjusting doses according to individual requirements and the routine monitoring of plasma or urine for patients under medication is highlighted.
 |
|